Randomized, Double-blind, Parallel-group Comparative Bioequivalence Trial of MabionCD20 (Mabion SA) Compared to MabThera (rituximab, Roche) in Patients with Rheumatoid Arthritis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 May 2020

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

26 May 2019 Status changed from recruiting to completed.
04 Jun 2018 According to a Mabion S.A. media release, the company has submitted Marketing Authorization Application for MabionCD20 to the European Medicines Agency (MEA). This application includes data from this trial.
06 Nov 2015 Planned primary completion date changed from 1 Mar 2016 to 1 Dec 2016, as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com